Charles Schwab Investment Management Inc Avalo Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $429 Billion
  • Q1 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$3.0 - $10.45 $235,248 - $819,447
-78,416 Reduced 57.93%
56,953 $29,000
Q1 2022

May 13, 2022
SELL
$7.57 - $21.72 $154,503 - $443,305
-20,410 Reduced 13.1%
135,369 $99,000
Q4 2021

Feb 11, 2022
BUY
$19.68 - $28.68 $453,919 - $661,504
23,065 Added 17.38%
155,779 $265,000
Q3 2021

Nov 16, 2021
BUY
$26.16 - $40.68 $3.47 Million - $5.4 Million
132,714 New
132,714 $290,000

Others Institutions Holding AVTX

# of Institutions
1
Shares Held
34.6K
Call Options Held
0
Put Options Held
0
View Full List

About Avalo Therapeutics, Inc.

AVTX Quotes by TradingView
  • Ticker AVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,414,100
  • Market Cap $118M
  • Description
  • Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...
More about AVTX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email